FDA-Approved Lymphoma CAR T-cell Therapies

Overview 

This guide section explains how FDA-approved CAR T-cell therapies for lymphoma work and discusses their common side effects. The sections are organized by lymphoma subtype. 

The current FDA-approved constructs available for lymphoma subtypes include: 

• Follicular lymphoma (FL)
  • Axicabtagene ciloleucel (axi-cel, Yescarta, Kite/Gilead)
  • Lisocabtagene maraleucel (liso-cel, Breyanzi, Juno Therapeutics/Bristol Myers Squibb)
  • Tisagenlecleucel (tisa-cel, Kymriah, Novartis)
• Large B-cell lymphoma (LBCL)
  • Axi-cel
  • Liso-cel
  • Tisa-cel
• Mantle cell lymphoma (MCL)
  • Brexucabtagene autoleucel (brexu-cel, Tecartus, Kite/Gilead)
  • Liso-cel
• Marginal zone lymphoma (MZL)
  • Liso-cel
• Small lymphocytic lymphoma (SLL)
  • Liso-cel 

Although other types of lymphoma do not yet have FDA-approved CAR T-cell therapies, clinical trials may be available that offer CAR-T for your specific type of lymphoma. Ask your lymphoma specialist about available trials. You can also learn more in our guide section: The Future of CAR-T for Lymphoma. 

The information in this guide should not take the place of having conversations with your lymphoma specialist about making treatment decisions. If you have questions about your lymphoma treatment, you can also contact our patient navigators here.